Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area.

Positive regulatory signals are converging with clinical wins and early-stage scientific advances to put neuroscience back on the radar, after long being viewed as too risky by investors and having been all but abandoned by pharmas...